US Justice Department Proposes Historic Reclassification of Marijuana

Regulations by 2FIRSTS.ai
May.17.2024
US Justice Department Proposes Historic Reclassification of Marijuana
U.S. Justice Department proposes historic reclassification of marijuana as safer drug, prompting potential benefits for research and cannabis industry.

According to a report by Reuters on May 17, the U.S. Department of Justice officially proposed a historic measure on Thursday (16th) to reclassify marijuana as a safer drug, stating that the risk of marijuana abuse is lower compared to other higher risk substances. If this regulation is enacted, it will also help facilitate further research on the medical benefits of marijuana.

 

The proposal states, "Furthermore, the FDA's review did not find any safety issues, indicating that the medical use of marijuana does not pose unacceptable high safety risks.

 

The Drug Enforcement Administration (DEA) in the United States is currently soliciting public feedback on the proposal, a process that may take some time, but Attorney General Merrick Garland has already given his approval. If approved, this new regulation would remove marijuana from the list of Schedule I drugs (which includes heroin, LSD, etc.) and reclassify it as a Schedule III drug, on par with ketamine and some synthetic steroids.

 

The department conducted a classification review of marijuana at the request of President Joe Biden in 2022. Additionally, Biden has taken steps to pardon thousands of individuals who were sentenced at the federal level for possession of marijuana, and has urged governors and mayors to take similar actions to commute these sentences. He hopes that this move will increase support for the Democratic party in an election year, especially among younger voters. Biden has promised, "Too many lives have been put in jeopardy due to the mishandling of marijuana, and I am committed to correcting these mistakes. You can trust my word."

 

Previously, the Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS) had recommended in August 2023 that the DEA classify marijuana as a Schedule III drug. The DEA has yet to make a specific classification for marijuana.

 

If the federal government relaxes marijuana classification, marijuana companies stand to benefit, such as being eligible to list on major stock exchanges and receive more generous tax breaks. Additionally, the banking restrictions they face may be reduced. Because marijuana is illegal at the federal level, most American banks do not provide loans or services to marijuana companies, prompting many banks to rely on cash transactions.

 

The public will have 60 days to submit comments on the proposal from the Department of Justice, and can also request a public hearing to be held on the proposal.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
Ireland Vape Retailers’ Group RVI Calls for Tax Stamps to Strengthen Enforcement of Vape Products Tax
Ireland Vape Retailers’ Group RVI Calls for Tax Stamps to Strengthen Enforcement of Vape Products Tax
Responsible Vaping Ireland (RVI), an Irish vape retailers’ group, has released a policy paper urging Ireland to swiftly introduce Revenue-issued tax stamps on vaping products to strengthen enforcement of the E-Liquid Products Tax (EPT) and to tackle tax evasion and the illicit market. Provisional Department of Finance figures show €1.3 million collected in November and December 2025; at that pace, annualised receipts would be €7.8 million, below the government’s projected €17 million.
Feb.26 by 2FIRSTS.ai
Scottish retailers call for tougher action as illegal vape black market “deepens,” SGF says
Scottish retailers call for tougher action as illegal vape black market “deepens,” SGF says
Scottish retailers, through the Scottish Grocers’ Federation (SGF), are calling for tougher action and more investment to tackle a “deepening black market” in illegal vapes, including illegal sales to children. SGF warns the problem will worsen, with negative health impacts, if incoming regulations on vaping product sales are not carefully crafted and if shopkeepers’ views are not heard.
Jan.14 by 2FIRSTS.ai
Daegu Jung-gu: liquid e-cigarettes with synthetic nicotine to be fined in nonsmoking areas under revised Tobacco Business Act
Daegu Jung-gu: liquid e-cigarettes with synthetic nicotine to be fined in nonsmoking areas under revised Tobacco Business Act
Daegu’s Jung-gu District announced on Feb. 10 that, following amendments to the Tobacco Business Act that explicitly classify liquid e-cigarettes containing synthetic nicotine as “tobacco” (effective April 24, 2026), the district will expand regulations to include fines for vaping such products in designated nonsmoking areas. The district health office said smokers/vapers could face an administrative fine of up to 100,000 won for using synthetic-nicotine liquid e-cigarettes in smoke-free zones
Feb.10 by 2FIRSTS.ai